435 related articles for article (PubMed ID: 27705912)
21. Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma.
Tian F; Li D; Chen J; Liu W; Cai L; Li J; Jiang P; Liu Z; Zhao X; Guo F; Li X; Wang S
Eur J Cancer; 2013 May; 49(7):1771-80. PubMed ID: 23313142
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of ZNF703 facilitates tumorigenesis and predicts unfavorable prognosis in patients with cholangiocarcinoma.
Li K; Wang J; Han J; Lan Y; Xie C; Pan S; Liu L
Oncotarget; 2016 Nov; 7(46):76108-76117. PubMed ID: 27764785
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification.
Liu C; Liu L; Shan J; Shen J; Xu Y; Zhang Q; Yang Z; Wu L; Xia F; Bie P; Cui Y; Zhang X; Bian X; Qian C
Cancer Lett; 2013 Oct; 339(1):60-9. PubMed ID: 23879963
[TBL] [Abstract][Full Text] [Related]
26. Downregulated circular RNA hsa_circ_0001649 regulates proliferation, migration and invasion in cholangiocarcinoma cells.
Xu Y; Yao Y; Zhong X; Leng K; Qin W; Qu L; Cui Y; Jiang X
Biochem Biophys Res Commun; 2018 Feb; 496(2):455-461. PubMed ID: 29337065
[TBL] [Abstract][Full Text] [Related]
27. Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer.
Wei TT; Lin YT; Chen WS; Luo P; Lin YC; Shun CT; Lin YH; Chen JB; Chen NW; Fang JM; Wu MS; Yang KC; Chang LC; Tai KY; Liang JT; Chen CC
EBioMedicine; 2016 Aug; 10():124-36. PubMed ID: 27448759
[TBL] [Abstract][Full Text] [Related]
28. TACC3 promotes colorectal cancer tumourigenesis and correlates with poor prognosis.
Du Y; Liu L; Wang C; Kuang B; Yan S; Zhou A; Wen C; Chen J; Wu Y; Yang X; Feng G; Liu B; Iwamoto A; Zeng M; Wang J; Zhang X; Liu H
Oncotarget; 2016 Jul; 7(27):41885-41897. PubMed ID: 27248823
[TBL] [Abstract][Full Text] [Related]
29. Sprouty4 correlates with favorable prognosis in perihilar cholangiocarcinoma by blocking the FGFR-ERK signaling pathway and arresting the cell cycle.
Qiu B; Chen T; Sun R; Liu Z; Zhang X; Li Z; Xu Y; Zhang Z
EBioMedicine; 2019 Dec; 50():166-177. PubMed ID: 31761616
[TBL] [Abstract][Full Text] [Related]
30. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
[TBL] [Abstract][Full Text] [Related]
31. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
33. The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming.
Xu L; Wang L; Zhou L; Dorfman RG; Pan Y; Tang D; Wang Y; Yin Y; Jiang C; Zou X; Wu J; Zhang M
Neoplasia; 2019 May; 21(5):429-441. PubMed ID: 30933885
[TBL] [Abstract][Full Text] [Related]
34. A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate.
Akbulut O; Lengerli D; Saatci O; Duman E; Seker UOS; Isik A; Akyol A; Caliskan B; Banoglu E; Sahin O
Mol Cancer Ther; 2020 Jun; 19(6):1243-1254. PubMed ID: 32217742
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells.
Feng L; Pan M; Sun J; Lu H; Shen Q; Zhang S; Jiang T; Liu L; Jin W; Chen Y; Wang X; Jin H
J Mol Med (Berl); 2013 Jan; 91(1):49-58. PubMed ID: 22763818
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
[TBL] [Abstract][Full Text] [Related]
37. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
38. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
[TBL] [Abstract][Full Text] [Related]
39. Significance of S100P as a biomarker in diagnosis, prognosis and therapy of opisthorchiasis-associated cholangiocarcinoma.
Wu Z; Boonmars T; Nagano I; Boonjaraspinyo S; Srinontong P; Ratasuwan P; Narong K; Nielsen PS; Maekawa Y
Int J Cancer; 2016 Jan; 138(2):396-408. PubMed ID: 26312563
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.
Yang R; Chen Y; Tang C; Li H; Wang B; Yan Q; Hu J; Zou S
BMC Cancer; 2014 Dec; 14():917. PubMed ID: 25479763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]